Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC148 in locally advanced or metastatic NSCLC
NCT06883630Phase 1Active, not recruiting
- Sponsor
- RemeGen
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of RC148 in non-small cell lung cancer (NSCLC), sponsored by RemeGen. Primary endpoint: Objective Response Rate at 24 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
RC148
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06883630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06883630.